[Antitumor research on human laryngeal carcinoma with combined application of VP3 gene, IL-18 gene and HN gene].
OBJECTIVE
To research the antitumor efficacy on mice model bearing H22 tumor with application of pVVP3IL-18HN and its mechanism of the antitumor effect on Hep-2.


METHODS
pVVP3IL-18HN was introduced into Hep-2 cells by liposome, then cellular morphology was observed through AO/EB stain. To evaluate the mechanism of the antitumor effect on Hep-2 of pVVP3IL-18HN and its effect on tumor immunogenicity, flow cytometer (FCM) was used to detect the variation of mitochondrial trans-membrane potential,reactive oxygen species (ROS) and the MHC-I. C57BL/6 mice were subcutaneously inoculated with 2 X 10(5) H22 tumor cells in the right hindlimb, and 7, 14 and 21 day post-inoculation, pVVP3IL-18HN was administrated intratumorally. The pVVP3, pVIL-18, PVHN and PBS control group were treated as above. Then the tumor suppression and specific cytotoxic T lymphocyte (CTL) activity was detected.


RESULTS
After the transfection of pVVP3IL-18HN, tumor cells crenated and stained by AO/EB. In the research pVVP3IL-18HN was found to up-regulate the value of ROS and the expression of MHC-I, and down-regulate the value of mitochondrial trans-membrane potential. The tumor suppression rate of pVVP3IL-18HN was 60.5% and a dramatically increased tumor suppression was revealed in the pVVP3IL-18HN treated mice as compared with control mice treated with PBS (P < 0.05).


CONCLUSIONS
pVVP3IL-18HN kill the tumor cells by apoptosis and have notable antitumor effect in vivo.
Guan
Guofang
G
Department of Otolaryngology, the Second Hospital, Bethune Faculty of Medical Sciences of Jilin University, Changchun, 130041, China.
Jin
Ningyi
N
Mi
Zhiqiang
Z
Li
Xiao
X
Lian
Hai
H
Jin
Chunshun
C
Sun
Lili
L
Wen
Lianji
L
D000818:Animals; D017209:Apoptosis; D019496:Cancer Vaccines / Q000235:genetics / Q000494:pharmacology*; D045744:Cell Line, Tumor; D015316:Genetic Therapy; D006801:Humans; D020382:Interleukin-18 / Q000235:genetics*; D007822:Laryngeal Neoplasms / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D014162:Transfection; D019444:Vaccines, DNA / Q000235:genetics / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
D019496:Cancer Vaccines; D020382:Interleukin-18; D019444:Vaccines, DNA